Johnson & Johnson beat earnings expectations in the final quarter of 2022 even as a strong dollar and sinking COVID-19 vaccine sales hurt revenue.
The health care giant also debuted on Tuesday a better-than-expected 2023 earnings forecast.
The Johnson & Johnson logo appears above a trading post on the floor of the New York Stock Exchange on July 12, 2021. Richard Drew/AP Photo
